120 related articles for article (PubMed ID: 17683651)
1. Prevention of bone metastases and management of bone health in early breast cancer.
Gnant M; Hadji P
Breast Cancer Res; 2010; 12(6):216. PubMed ID: 21172067
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonates as anticancer agents in early breast cancer: preclinical and clinical evidence.
Santini D; Stumbo L; Spoto C; D'Onofrio L; Pantano F; Iuliani M; Fioramonti M; Zoccoli A; Ribelli G; Virzì V; Vincenzi B; Tonini G
Breast Cancer Res; 2015 Sep; 17(1):121. PubMed ID: 26328589
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonate and risk of cancer recurrence: protocol for a systematic review, meta-analysis and trial sequential analysis of randomised controlled trials.
Liu Y; Du C; Zhang Y; Zhao S; Zhao L; Li P; Hu F; Zhu L; Liu Y; Pang D; Zhao Y
BMJ Open; 2015 Apr; 5(4):e007215. PubMed ID: 25900461
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.
Gnant M; Pfeiler G; Dubsky PC; Hubalek M; Greil R; Jakesz R; Wette V; Balic M; Haslbauer F; Melbinger E; Bjelic-Radisic V; Artner-Matuschek S; Fitzal F; Marth C; Sevelda P; Mlineritsch B; Steger GG; Manfreda D; Exner R; Egle D; Bergh J; Kainberger F; Talbot S; Warner D; Fesl C; Singer CF;
Lancet; 2015 Aug; 386(9992):433-43. PubMed ID: 26040499
[TBL] [Abstract][Full Text] [Related]
5. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.
Stopeck AT; Lipton A; Body JJ; Steger GG; Tonkin K; de Boer RH; Lichinitser M; Fujiwara Y; Yardley DA; Viniegra M; Fan M; Jiang Q; Dansey R; Jun S; Braun A
J Clin Oncol; 2010 Dec; 28(35):5132-9. PubMed ID: 21060033
[TBL] [Abstract][Full Text] [Related]
6. Heparan sulfate proteoglycans as targets for cancer therapy: a review.
Onyeisi JOS; Ferreira BZF; Nader HB; Lopes CC
Cancer Biol Ther; 2020 Dec; 21(12):1087-1094. PubMed ID: 33180600
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy of denosumab versus bisphosphonates for the prevention of bone complications: implications for nursing.
Campbell-Baird C; Harrelson S; Frey G; Balakumaran A
Support Care Cancer; 2015 Dec; 23(12):3625-32. PubMed ID: 26298333
[TBL] [Abstract][Full Text] [Related]
8. Elevated incidence of fractures in women with invasive breast cancer.
Edwards BJ; Gradishar WJ; Smith ME; Pacheco JA; Holbrook J; McKoy JM; Nardone B; Tica S; Godinez-Puig V; Rademaker AW; Helenowski IB; Bunta AD; Stern PH; Rosen ST; West DP; Guise TA
Osteoporos Int; 2016 Feb; 27(2):499-507. PubMed ID: 26294292
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the efficacy and safety of denosumab versus bisphosphonates in breast cancer and bone metastases treatment: A meta-analysis of randomized controlled trials.
Wang X; Yang KH; Wanyan P; Tian JH
Oncol Lett; 2014 Jun; 7(6):1997-2002. PubMed ID: 24932278
[TBL] [Abstract][Full Text] [Related]
10. A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease.
Coleman R; Aksnes AK; Naume B; Garcia C; Jerusalem G; Piccart M; Vobecky N; Thuresson M; Flamen P
Breast Cancer Res Treat; 2014 Jun; 145(2):411-8. PubMed ID: 24728613
[TBL] [Abstract][Full Text] [Related]
11. Zoledronic acid as an adjuvant therapy in patients with breast cancer: a systematic review and meta-analysis.
Huang WW; Huang C; Liu J; Zheng HY; Lin L
PLoS One; 2012; 7(7):e40783. PubMed ID: 22844410
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Bone Metastases in Patients with Advanced Breast Cancer.
Gnant M; Balic M; Petru E; Raunik W; Singer CF; Steger GG; Watzke IM; Brodowicz T
Breast Care (Basel); 2012 Apr; 7(2):92-98. PubMed ID: 22740794
[TBL] [Abstract][Full Text] [Related]
13. Behavioral, medical imaging and histopathological features of a new rat model of bone cancer pain.
Doré-Savard L; Otis V; Belleville K; Lemire M; Archambault M; Tremblay L; Beaudoin JF; Beaudet N; Lecomte R; Lepage M; Gendron L; Sarret P
PLoS One; 2010 Oct; 5(10):e13774. PubMed ID: 21048940
[TBL] [Abstract][Full Text] [Related]
14. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer.
Coleman RE; Winter MC; Cameron D; Bell R; Dodwell D; Keane MM; Gil M; Ritchie D; Passos-Coelho JL; Wheatley D; Burkinshaw R; Marshall SJ; Thorpe H;
Br J Cancer; 2010 Mar; 102(7):1099-105. PubMed ID: 20234364
[TBL] [Abstract][Full Text] [Related]
15. Potential antitumor effects of nitrogen-containing bisphosphonate in hormone receptor negative breast cancer patients with bone metastases.
Park IH; Ro J; Nam BH; Kwon Y; Lee KS
BMC Cancer; 2009 May; 9():154. PubMed ID: 19454038
[TBL] [Abstract][Full Text] [Related]
16. Potential use of bisphosphonates in the prevention of metastases in early-stage breast cancer.
Coleman R
Clin Breast Cancer; 2007 Jul; 7 Suppl 1():S29-35. PubMed ID: 17683651
[TBL] [Abstract][Full Text] [Related]
17. Bisphosphonates as adjuvant therapy for breast cancer.
Burkinshaw R; Coleman R
Womens Health (Lond); 2006 Jan; 2(1):115-26. PubMed ID: 19803932
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant bisphosphonates in breast cancer: are we witnessing the emergence of a new therapeutic strategy?
Coleman RE
Eur J Cancer; 2009 Jul; 45(11):1909-15. PubMed ID: 19447606
[TBL] [Abstract][Full Text] [Related]
19. [The role of bisphosphonates of adjuvant therapy in breast cancer].
Gálvez-Muñoz E; Rodríguez-Lescure Á
Med Clin (Barc); 2010 Jun; 135(2):70-4. PubMed ID: 20022069
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
